Related Experiment Video
Updated: Feb 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Modeling combination chemo-immunotherapy for heterogeneous tumors
Shaoqing Chen1,2, Zheng Hu3, Da Zhou1,2
1School of Mathematical Sciences Xiamen University Xiamen China.
Abstract:
Hypermutable cancers create opportunities for the development of various immunotherapies, such as immune checkpoint blockade (ICB) therapy. However, emergent studies have revealed that many hypermutated tumors have poor prognosis due to heterogeneous tumor antigen landscapes, yet the underlying mechanisms remain poorly understood. To understand the mechanisms that govern the responses to therapies, we develop mathematical models to explore the impact of combining chemotherapy and ICB therapy on heterogeneous tumors. Our results uncover how chemotherapy reduces antigenic heterogeneity, creating improved immunological conditions within tumors, which, in turn, enhances the therapeutic effect when combined with ICB. Furthermore, our results show that the recovery of the immune system after chemotherapy is crucial for enhancing the response to chemo-ICB combination therapy.
Insights
Chemotherapy can improve immunotherapy for hypermutable cancers by reducing tumor antigen diversity. Restoring the immune system post-chemotherapy is key for effective combination cancer treatment.
Area of Science:
- Oncology
- Immunotherapy
- Mathematical Biology
Background:
- Hypermutable cancers offer potential for immunotherapies like immune checkpoint blockade (ICB).
- However, many hypermutated tumors exhibit poor prognosis due to diverse tumor antigen landscapes, with mechanisms poorly understood.
- Understanding these mechanisms is crucial for developing effective cancer treatments.
Purpose of the Study:
- To investigate the mechanisms governing treatment responses in heterogeneous tumors.
- To explore the impact of combining chemotherapy and ICB therapy on hypermutable, antigenically diverse tumors using mathematical modeling.
Main Methods:
- Development of mathematical models to simulate tumor-immune dynamics.
- Analysis of the effects of chemotherapy on tumor antigenic heterogeneity.
- Evaluation of the combined impact of chemotherapy and ICB therapy.
Main Results:
- Chemotherapy was found to reduce antigenic heterogeneity within tumors.
- This reduction in heterogeneity creates more favorable immunological conditions for ICB therapy.
- The recovery of the immune system following chemotherapy is essential for enhancing the efficacy of combined chemo-ICB therapy.
Conclusions:
- Combining chemotherapy with ICB therapy can overcome poor prognosis in hypermutable cancers by reducing antigenic heterogeneity.
- Mathematical modeling provides insights into optimizing combination cancer immunotherapies.
- Immune system recovery post-chemotherapy is a critical factor for successful chemo-ICB treatment strategies.
More Related Videos
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Related Concept Videos
Tumor Immunotherapy
Combining Functions
Impedance Combination
Combination Of Resistors
Stresses under Combined Loadings
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...